Notice of Application to Vary the Conditions of a Registered Trade Name Product (Notice No. MPI 1665)
Maree Zinzley, Manager Approvals, of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”) that the following variation application has been made to a registered trade name product under section 9(2) of the Act:
Trade Name: ProZinc Insulin Injection for Cats
Reference: A011421
Active Ingredient and Concentration:
40 IU human insulin
Formulation Type: Aqueous Solution
Current Claims:
For the treatment of diabetes mellitus in cats to achieve reduction of hyperglycaemia and improvement of associated clinical signs.
Proposed New Claim (changes in bold):
For the treatment of diabetes mellitus in cats and dogs to achieve reduction of hyperglycaemia and improvement of associated clinical signs.
Any person may make a written submission to the director-general concerning this application.
Under sections 16 and 17 of the Act, a written submission:
Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.
The following address is:
ACVM Group, Ministry for Primary Industries, Charles Fergusson Building, 34–38 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.
The applicant’s address for service is:
Boehringer Ingelheim Animal Health New Zealand Limited, Level 3, 2 Osterley Way, Manukau, Auckland 2104. Postal Address: PO Box 76211, Manukau, Auckland 2241.
Dated at Wellington this 8th day of June 2023.
MAREE ZINZLEY, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).